drugset / Trial / NCT01511874
Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate efficacy and safety of ELIGARD 22.5mg in the treatment of subjects with prostate cancer.
Timeline
- Start
- 2011-01
- Primary completion
- 2013-05
- Completion
- 2013-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Leuprolide | Other / unclassified | 22.5 mg | Subcutaneous |